Iqvia Holdings Inc. (IQV): EPS (Diluted)
$7.84
Year ended 2025-12-31
+11.1%
3-year compound annual growth
+40.5%
5-year compound annual growth
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.84 | +4.7% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $7.49 | +2.7% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $7.29 | +27.4% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $5.72 | +15.6% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $4.95 | +246.2% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $1.43 | +49.0% | 2023-02-15, From 2020-01-01 |
| 2019-12-31 | $0.96 | -22.6% | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $1.24 | -78.4% | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | $5.74 | n/m | 2020-02-18, From 2017-01-01 |
| 2016-12-31 | $0.47 | n/c | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | $3.08 | +13.2% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $2.72 | +53.7% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $1.77 | +17.2% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $1.51 | -26.3% | 2015-02-12, From 2012-01-01 |
| 2011-12-31 | $2.05 | n/a | 2014-02-13, From 2011-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $7.84 | +4.7% |
| Icon PLC (ICLR) | 2025-12-31 | $2.90 | -67.4% |
| Incyte Corp (INCY) | 2025-12-31 | $6.41 | n/m |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | -$2.91 | n/m |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $15.28 | +21.0% |
| NRC Health (NRC) | 2025-12-31 | $50.00 | n/m |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$0.42 | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$0.57 | n/m |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | -$8.66 | n/m |
Compare IQV, ICLR, INCY, CRL side by side · Screen every company in Services-Commercial Physical & Biological Research ↗